Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Sep;74(6):961–963. doi: 10.1038/bjc.1996.465

Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.

J van Meerbeeck 1, C Debruyne 1, N van Zandwijk 1, P E Postmus 1, M C Pennucci 1, F van Breukelen 1, D Galdermans 1, H Groen 1, P Pinson 1, M van Glabbeke 1, E van Marck 1, G Giaccone 1
PMCID: PMC2074723  PMID: 8826866

Abstract

The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and antihistamines. This regimen was well tolerated, with < 4% of cycles resulting in severe toxicity. No major objective responses were observed and ten patients had stable disease. Median survival time was 39 weeks and the 1 year survival rate was 30%. In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.

Full text

PDF
961

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boutin C., Rey F., Gouvernet J., Viallat J. R., Astoul P., Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer. 1993 Jul 15;72(2):394–404. doi: 10.1002/1097-0142(19930715)72:2<394::aid-cncr2820720214>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  2. Calavrezos A., Koschel G., Hüsselmann H., Taylessani A., Heilmann H. P., Fabel H., Schmoll H. J., Dietrich H., Hain E. Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985. Klin Wochenschr. 1988 Jul 15;66(14):607–613. doi: 10.1007/BF01728801. [DOI] [PubMed] [Google Scholar]
  3. Gupta R. S. Taxol resistant mutants of Chinese hamster ovary cells: genetic biochemical, and cross-resistance studies. J Cell Physiol. 1983 Jan;114(1):137–144. doi: 10.1002/jcp.1041140122. [DOI] [PubMed] [Google Scholar]
  4. Krarup-Hansen A., Hansen H. H. Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol. 1991;28(5):319–330. doi: 10.1007/BF00685684. [DOI] [PubMed] [Google Scholar]
  5. Krarup-Hansen A. Phase II trials of malignant mesothelioma: a commentary and update. Lung Cancer. 1994 Sep;11(3-4):305–308. doi: 10.1016/0169-5002(94)90551-7. [DOI] [PubMed] [Google Scholar]
  6. Mattson K., Giaccone G., Kirkpatrick A., Evrard D., Tammilehto L., van Breukelen F. J., Planteydt H. T., van Zandwijk N. Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1992 May;10(5):824–828. doi: 10.1200/JCO.1992.10.5.824. [DOI] [PubMed] [Google Scholar]
  7. Pisani R. J., Colby T. V., Williams D. E. Malignant mesothelioma of the pleura. Mayo Clin Proc. 1988 Dec;63(12):1234–1244. doi: 10.1016/s0025-6196(12)65411-1. [DOI] [PubMed] [Google Scholar]
  8. Rowinsky E. K., Donehower R. C. Paclitaxel (taxol) N Engl J Med. 1995 Apr 13;332(15):1004–1014. doi: 10.1056/NEJM199504133321507. [DOI] [PubMed] [Google Scholar]
  9. Rowinsky E. K., Eisenhauer E. A., Chaudhry V., Arbuck S. G., Donehower R. C. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol. 1993 Aug;20(4 Suppl 3):1–15. [PubMed] [Google Scholar]
  10. Schiller J. H., Storer B., Tutsch K., Arzoomanian R., Alberti D., Feierabend C., Spriggs D. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol. 1994 Feb;12(2):241–248. doi: 10.1200/JCO.1994.12.2.241. [DOI] [PubMed] [Google Scholar]
  11. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1–10. doi: 10.1016/0197-2456(89)90015-9. [DOI] [PubMed] [Google Scholar]
  12. Van Meerbeeck J. P. Prognostic factors in malignant mesothelioma: where do we go from here? Eur Respir J. 1994 Jun;7(6):1029–1031. [PubMed] [Google Scholar]
  13. Vogelzang N. J. Malignant mesothelioma: diagnostic and management strategies for 1992. Semin Oncol. 1992 Aug;19(4 Suppl 11):64–71. [PubMed] [Google Scholar]
  14. van Breukelen F. J., Mattson K., Giaccone G., van Zandwijk N., Planteydt H. T., Kirkpatrick A., Dalesio O. Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1991;27(12):1627–1629. doi: 10.1016/0277-5379(91)90430-l. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES